Acromegaly Global Market is Projected to Increase Revenues Growth, Business Insights, Future Demand and Forecast 2024-2033 | Pfizer Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A.

The acromegaly market size has grown rapidly in recent years. It will grow from $1.79 billion in 2023 to $2.15 billion in 2024 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to increasing prevalence of acromegaly therapeutics, growing awareness about acromegaly, government initiatives, demand for effective treatments.

The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2028 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to investments in research and development activities for acromegaly treatments, growing number of screening programs, rising healthcare spending, increasing demand for minimally invasive treatment options. Major trends in the forecast period include innovative treatments for acromegaly, development of targeted therapies for acromegaly, strong pipeline of drugs, advancements in treatment options, advanced personalized medicine.

Market Overview -
Acromegaly is a rare hormonal disorder that occurs when the pituitary gland, a small gland located at the base of the brain, produces excessive growth hormone. This excess growth hormone leads to the enlargement and thickening of bones and tissues in various body parts, particularly the hands, feet and face.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market
The growing number of hormonal diseases such as diabetes is expected to propel the growth of the acromegaly market going forward. Hormonal diseases, also known as endocrine disorders, are medical conditions that result from dysfunction in the endocrine system. Diabetes is one of the most prevalent and significant hormonal diseases. Acromegaly and other endocrine diseases can result from the overproduction of some hormones, such as growth hormone or cortisol. Additionally, due to the impact of high amounts of growth hormone on insulin synthesis, about 50% of people with acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20-79 years old) in 2021 and it is predicted that the number will reach 643 million people by 2030 and a total of 783 million by 2045. Therefore, the growing number of hormonal diseases is driving the growth of the acromegaly market.

Competitive Landscape -
Major players in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Innovative Solutions Drive Market Dominance In Acromegaly Treatment
Major companies operating in the acromegaly market are focused on developing innovative products and solutions, such as generic lanreotide, to gain competitive advantages and sustain their position in the market. For instance, in July 2021, Advanz Pharma Corp., a UK-based pharmaceutical company, launched Mytolac (lanreotide) in Germany, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumors. Lanreotide is recommended for treating acromegaly patients whose circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are still abnormal after surgery, radiation, or other medical treatment or in patients who otherwise need care.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Key Segments -
The acromegaly market covered in this report is segmented -
1) By Type: Ectopic Acromegaly; Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement; Growth Hormone Suppression Test; Imaging; Other Diagnosis
3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
4) By Treatment: Medication; Somatostatin analogues; Dopamine Agonists; Growth Hormone Antagonist; Surgery; Radiation; Other Treatments
5) By End Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.